Clinical Study Shows That Retinal Imaging May Detect Signs of Alzheimer’s Disease
Researchers at Cedars-Sinai and NeuroVision LLC Publish Proof of Concept Study on Experimental Optical Imaging System, Demonstrating Detection of Retinal Beta-Amyloid, a Hallmark of Alzheimer’s Disease
A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer’s. The experimental technology, developed by Cedars-Sinai and NeuroVision, scans the retina using techniques that can identify beta-amyloid protein deposits that mirror those in the brain.
Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.
2019 AANS/CNS Section on Pediatric Neurological Surgery Annual Meeting
Dec. 5-8, 2019; Scottsdale, Ariz.
Dec. 5-8, 2019; Mumbai, India
7th Emirates International Neurosurgical Conference
Dec. 12-14, 2019; Dubai, United Arab Emirates